HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Immunohistochemical molecular expression profile of metastatic brain tumor for potent personalized medicine

Files in This Item:
BTPepab.pdf1.39 MBPDFView/Open
Please use this identifier to cite or link to this item:

Title: Immunohistochemical molecular expression profile of metastatic brain tumor for potent personalized medicine
Authors: Kato, Yasutaka Browse this author
Nishihara, Hiroshi Browse this author →KAKEN DB
Yuzawa, Sayaka Browse this author
Mohri, Hiromi Browse this author
Kanno, Hiromi Browse this author
Hatanaka, Yutaka Browse this author →KAKEN DB
Kimura, Taichi Browse this author →KAKEN DB
Tanino, Mishie Browse this author →KAKEN DB
Tanaka, Shinya Browse this author →KAKEN DB
Keywords: Metastatic brain tumor
Molecular expression profile
Personalized medicine
Issue Date: Jul-2013
Publisher: Springer Japan
Journal Title: Brain Tumor Pathology
Volume: 30
Issue: 3
Start Page: 167
End Page: 174
Publisher DOI: 10.1007/s10014-012-0124-y
PMID: 23180004
Abstract: Recent progress in molecule-targeting therapy may yield personalized therapeutic strategies for patients with metastatic brain tumors (MBT), the most frequently encountered intracranial tumors. For this purpose, we investigated the molecular expression profile of MBT to establish the pathological basis for personalized diagnosis. We studied 166 MBT specimens including 70 cases of lung cancer and 34 cases of breast cancer, and performed immunostaining for EGFR, COX-2, and O-6-methylguanine-DNA methyltransferase (MGMT), among others, which could be target molecules for therapeutic agents or enable prediction of drug efficacy. Loss of MGMT expression was observed in approximately 20–40 % of MBT derived from lung, breast, and gastrointestinal cancers, indicating the possibility of treatment of MBT patients with temozolomide. In addition, MBT expressed a variety of receptor tyrosine kinases, for example EGFR and HER2, and signal transduction molecules, for example phospho-mTOR and COX-2, irrespective of tumor origin, enabling individualized medication with molecule-targeting drugs. We also identified alteration of molecular expression profile in 4 MBT cases during recurrence. Our results not only reveal the molecular characteristics of MBT but also suggest the possibility of potent personalized medicine for MBT patients.
Rights: The final publication is available at
Type: article (author version)
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 西原 広史

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


Feedback - Hokkaido University